{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:49:02Z","timestamp":1776088142337,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072915"],"award-info":[{"award-number":["82072915"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373359"],"award-info":[{"award-number":["82373359"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chidamide is a selective histone deacetylase inhibitor approved for patients with hormone receptor (HoR)\u2010positive and HER2\u2010negative metastatic breast cancer (MBC). We aimed to investigate the efficacy, safety, and treatment patterns of chidamide and identify clinicopathological factors that predict the efficacy of chidamide in real\u2010world scenarios.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive MBC patients treated with chidamide from January 2020 to August 2021 across 11 institutions were enrolled in this multicenter, retrospective study. Eligible patients were pre\u2010 and postmenopausal women who had clinically or histologically confirmed ER\u2010positive, HER2\u2010negative MBC, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients with multiple primary malignancies or missing baseline characteristics were excluded. Patients received 30\u2009mg chidamide orally twice a week, combined with aromatase inhibitors (AIs) or non\u2010AIs. Efficacy analyses included progression\u2010free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR). Univariate and multivariate Cox regression analyses were performed to identify the potential efficacy predictors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 157 patients were finally included for analysis. The median number of lines prior to chidamide was four. In the whole cohort, the median PFS was 4.2\u2009months (95% confidence interval [CI] 3.8\u20134.5). The ORR was 7.5% and the CBR was 31.3%. The efficacy of chidamide was consistent in patients pretreated with CDK4\/6 inhibitors and patients treated with different endocrine combinations. Multivariate analysis indicated that patients who had liver metastases (adjusted HR\u2009=\u20091.66, 95% CI 1.14\u20132.43, adjusted <jats:italic>p<\/jats:italic>\u2009=\u20090.008) or \u22653 prior lines of treatment (adjusted HR\u2009=\u20091.80, 95% CI 1.17\u20132.77, adjusted <jats:italic>p<\/jats:italic>\u2009=\u20090.008) had significantly worse PFS. The most common AEs with chidamide were thrombocytopenia, leucopenia, neutropenia, and anemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provided real\u2010world data for the use of chidamide in patients with HoR\u2010positive and HER2\u2010negative MBC. Our data endorsed the use of chidamide in patients pretreated with CDK4\/6 inhibitors and patients treated with different endocrine combinations.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6762","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T16:00:22Z","timestamp":1709913622000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor\u2010positive, <scp>HER2<\/scp>\u2010negative metastatic breast cancer: A real\u2010world multicenter study"],"prefix":"10.1002","volume":"13","author":[{"given":"Doudou","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"},{"name":"MN. Office of Clinical Research Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-4187","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"},{"name":"Phase I Clinical Trial Center Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","unstructured":"DeSantisCE MaJ GaudetMM et\u00a0al.CA Cancer J Clin.2019;69:438\u2010451. doi:10.3322\/caac.21583","DOI":"10.3322\/caac.21583"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0620"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.009"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-2458"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-13-0345"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1766-x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20306"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-016-4005-z"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2018.06.05"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30164-0"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71159-3"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00613-0"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30292-4"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.9909"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.7585"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.6155"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01562-9"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211022890"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.12.017"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.10.021"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.156"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.43.7251"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T05:04:30Z","timestamp":1710219870000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/cam4.6762"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6762","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e6762"}}